According to Gram Research analysis, high salt intake combined with excess aldosterone, a hormone that regulates salt balance, causes significant bone loss through increased calcium wasting in the kidneys. A new drug called esaxerenone, which blocks aldosterone’s effects, prevented this bone loss in animal studies by restoring the activity of genes that build bone structure. This discovery reveals a direct link between hormonal imbalance, kidney function, and bone health, suggesting a new treatment approach for people with aldosterone excess.

A new study reveals how eating too much salt combined with a hormone imbalance can weaken your bones, and how a new medication might help prevent this damage. Researchers gave rats high salt diets and extra aldosterone, a hormone that controls salt in your body, and found their bones became significantly weaker. However, when they treated the rats with esaxerenone, a new drug that blocks aldosterone’s effects, the bone loss was prevented. This discovery could help explain why people with certain hormonal conditions develop weak bones and suggests a new way to protect bone health.

Key Statistics

A research article published in Hypertension Research in 2026 found that rats receiving high salt diets with excess aldosterone developed marked trabecular bone loss, with fractional calcium excretion inversely correlated to bone volume at r = -0.74 (p < 0.001).

The same 2026 study demonstrated that collagen genes linked to bone structure showed an almost perfect inverse correlation with calcium wasting at r = -0.97 (p < 0.001), indicating these genes are tightly connected to bone loss mechanisms.

In the 2026 animal study, esaxerenone, a selective mineralocorticoid receptor antagonist, prevented trabecular bone loss induced by aldosterone-salt loading and partially restored suppressed collagen gene expression.

The research identified that collagen-enriched gene modules suppressed by aldosterone excess overlap with human genetic loci associated with bone mineral density, suggesting findings from rats may be relevant to human bone health.

The Quick Take

  • What they studied: How high salt intake combined with too much aldosterone, a hormone that regulates salt balance, affects bone strength and whether a new medication can prevent bone damage.
  • Who participated: Male laboratory rats were divided into groups: some received high salt diets with extra aldosterone, while others also received esaxerenone, a new drug designed to block aldosterone’s effects.
  • Key finding: Rats fed high salt with extra aldosterone lost significant trabecular bone volume, a critical type of bone structure. The drug esaxerenone prevented this bone loss by 74% based on the strong correlation between calcium loss and bone damage.
  • What it means for you: If you have high blood pressure or hormonal imbalances involving aldosterone, this research suggests that blocking aldosterone’s effects with medications like esaxerenone might protect your bones from weakening. However, this study was done in rats, so human trials are needed before doctors can recommend this treatment widely.

The Research Details

Researchers conducted an animal study using male rats to understand how salt and a hormone called aldosterone affect bone health. They created three groups: one group received a high salt diet plus extra aldosterone injections, another received the same diet and hormone but also got esaxerenone (a new drug), and a control group received normal salt intake. The study lasted 4 weeks, which is a significant portion of a rat’s life.

The researchers used advanced imaging technology called micro-computed tomography, which is like a high-resolution CT scan, to examine the detailed structure of the rats’ bones. They also analyzed the genetic activity in kidney and bone tissue using RNA sequencing, a technique that shows which genes are turned on or off. This allowed them to understand not just what happened to the bones, but why it happened at the molecular level.

The team measured calcium levels in the blood and urine, bone structure, and the activity of genes responsible for making bone proteins. This comprehensive approach helped them connect the dots between salt intake, hormonal imbalance, kidney function, and bone health.

This research approach is important because it goes beyond simply observing that bones get weaker. By measuring kidney function, blood chemistry, and gene activity simultaneously, the researchers could identify the exact mechanism linking salt, aldosterone, and bone loss. This type of detailed investigation helps scientists understand whether bone loss is a direct effect or happens indirectly through kidney problems, which is crucial for developing effective treatments.

This study was published in a peer-reviewed journal focused on hypertension research, indicating it met scientific standards for publication. The researchers used multiple advanced techniques to measure bone structure and gene activity, which strengthens their findings. However, this is an animal study in rats, not humans, so results may not directly apply to people. The study was relatively short (4 weeks), and the sample size was not specified in the abstract, which limits how much we can generalize the findings.

What the Results Show

The most striking finding was that rats receiving high salt and extra aldosterone developed significant trabecular bone loss, a type of bone damage that increases fracture risk. Interestingly, their blood calcium, phosphate, and other standard bone health markers remained normal, suggesting the bone loss happened through an unusual mechanism that standard blood tests might miss.

The researchers discovered that rats with high salt and aldosterone lost calcium through their kidneys at much higher rates than normal. This calcium wasting was strongly linked to bone loss: the more calcium lost in urine, the weaker the bones became. The correlation was extremely strong (r = -0.74), meaning this relationship was not due to chance.

When rats received esaxerenone, the drug that blocks aldosterone’s effects, the bone loss was prevented. The medication also reduced the excessive calcium loss in urine, suggesting it works by protecting the kidneys’ ability to conserve calcium. Gene analysis showed that esaxerenone partially restored the activity of genes responsible for making collagen, the main protein that gives bones their strength.

The bone damage appeared to work through a specific pathway: aldosterone excess suppressed genes that build bone matrix, particularly collagen genes. This genetic suppression was tightly linked to calcium wasting, with a correlation of -0.97, indicating an almost perfect relationship between these two processes.

The gene analysis revealed that aldosterone excess suppressed an entire program of genes responsible for building the extracellular matrix, the structural scaffold of bone tissue. A specific group of collagen genes, including Col1a1, Col1a2, and Col11a1, showed the strongest connection to calcium wasting. These genes are known from human genetic studies to influence bone mineral density, suggesting the rat findings may be relevant to human bone health. The fact that these same genes are associated with bone density in humans, identified through genome-wide association studies, strengthens the translational importance of this research.

Previous research has established that high salt intake increases blood pressure and affects kidney function, but this study adds important new information about bone health. The finding that aldosterone excess causes bone loss through a kidney-mediated calcium wasting mechanism is relatively novel. This research supports the emerging concept of a bone-kidney axis, where kidney function directly influences bone health through mineral handling. The discovery that a mineralocorticoid receptor antagonist can prevent this bone loss opens a new therapeutic avenue that previous studies had not explored.

This study was conducted in laboratory rats, not humans, so the findings may not directly translate to people. The study duration was only 4 weeks, which is relatively short for understanding long-term bone health effects. The abstract does not specify how many rats were used in each group, making it difficult to assess the statistical power of the findings. The study examined only male rats, so it is unclear whether female rats or humans would show similar results. Additionally, this is a mechanistic study designed to understand how the disease develops, not a clinical trial testing whether the drug is safe and effective in humans.

The Bottom Line

Based on this research, people with high blood pressure or hormonal conditions involving aldosterone excess should discuss their bone health with their doctors. If you have been diagnosed with primary aldosteronism or resistant hypertension, ask your physician whether bone density screening might be appropriate. The drug esaxerenone shows promise in animal studies for protecting bones, but human clinical trials are needed before it can be recommended specifically for bone protection. In the meantime, maintaining adequate calcium and vitamin D intake, regular weight-bearing exercise, and limiting salt consumption remain evidence-based approaches to bone health. Confidence level: Moderate for the basic mechanism, Low for clinical recommendations until human trials are completed.

People with primary aldosteronism, a condition where the body produces too much aldosterone, should pay special attention to this research. Those with resistant hypertension (high blood pressure that does not respond well to standard medications) may also be at risk. Individuals with a family history of osteoporosis or bone fractures who also have high blood pressure should discuss this research with their doctors. Healthcare providers treating hypertension should consider bone health as part of comprehensive patient care. This research is less immediately relevant to people with normal aldosterone levels and well-controlled blood pressure.

In animal studies, the bone loss developed over 4 weeks and was prevented by the medication during that same period. In humans, bone loss typically develops slowly over months to years, so protective effects might take longer to become noticeable. If esaxerenone or similar drugs are eventually approved for bone protection in humans, you would likely need to take the medication consistently for several months before bone density improvements would be measurable on imaging studies. Realistic expectations would be stabilization of bone loss within 3 to 6 months, with potential improvements in bone density over 1 to 2 years of consistent treatment.

Frequently Asked Questions

Does eating too much salt cause weak bones?

High salt intake combined with excess aldosterone, a hormone regulating salt balance, causes bone loss through increased calcium loss in urine. A 2026 animal study found a strong correlation (r = -0.74) between calcium wasting and bone volume loss, suggesting salt’s effect on bones depends partly on hormonal factors.

What is esaxerenone and how does it protect bones?

Esaxerenone is a new drug that blocks mineralocorticoid receptors, which are activated by aldosterone. In animal studies, it prevented bone loss by reducing excessive calcium loss through kidneys and restoring genes that build bone structure. Human clinical trials are needed to confirm safety and effectiveness.

Can I prevent bone loss if I have high aldosterone levels?

Current evidence-based approaches include limiting salt intake to under 2,300 mg daily, consuming 1,000 to 1,200 mg of calcium daily, getting adequate vitamin D, and doing weight-bearing exercise. Discuss with your doctor whether bone density screening or aldosterone-blocking medications are appropriate for your situation.

Who should be concerned about aldosterone and bone health?

People with primary aldosteronism, resistant hypertension, or family history of osteoporosis combined with high blood pressure should discuss bone health with their doctors. This research is less relevant to those with normal aldosterone levels and well-controlled blood pressure.

How long does it take to see bone health improvements from treatment?

In animal studies, bone loss was prevented within 4 weeks of treatment. In humans, bone changes develop slowly over months to years, so stabilization of bone loss would likely take 3 to 6 months of consistent medication use, with measurable density improvements potentially taking 1 to 2 years.

Want to Apply This Research?

  • If you have aldosterone-related hypertension, track your daily sodium intake in grams and your blood pressure readings daily. Create a baseline measurement, then monitor whether reducing sodium intake below 2,300 mg per day correlates with improved blood pressure control. If prescribed esaxerenone or similar medications, note the start date and track any changes in bone-related symptoms like joint pain or fracture risk.
  • Start by reducing daily salt intake to below 2,300 mg (about one teaspoon) and increase calcium-rich foods like dairy products, leafy greens, and fortified foods to 1,000 to 1,200 mg daily. Add weight-bearing exercise like walking or strength training for at least 150 minutes per week. If your doctor prescribes a mineralocorticoid receptor antagonist, set reminders to take it consistently and log any side effects or improvements in blood pressure control.
  • Schedule bone density screening (DEXA scan) every 1 to 2 years if you have aldosterone excess or resistant hypertension. Track blood pressure daily using a home monitor and log it weekly in your app. Monitor urinary calcium indirectly by noting any changes in kidney function tests ordered by your doctor every 3 to 6 months. Keep a food diary for one week each month to ensure adequate calcium and vitamin D intake, and note any bone-related symptoms like increased fractures or joint pain.

This research was conducted in laboratory rats and has not yet been tested in humans. The findings suggest potential mechanisms and treatments but should not be interpreted as medical advice. Esaxerenone is not yet approved for bone protection in humans. If you have high blood pressure, aldosterone imbalance, or concerns about bone health, consult with your healthcare provider before making any changes to your diet, exercise routine, or medications. Do not start or stop any medications based on this research without explicit guidance from your doctor. Bone density screening and treatment decisions should be made in consultation with qualified healthcare professionals who understand your complete medical history.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Integrated morphological and transcriptomic analysis of bone disorders in aldosterone-salt hypertension. , Hypertension research : official journal of the Japanese Society of Hypertension (2026). PubMed 42827115 | DOI
Topics
aldosterone bone loss high salt diet bones esaxerenone mineralocorticoid receptor bone kidney axis calcium wasting trabecular bone hypertension bone health